Boston Scientific Corporation (bsx)

BSX — Company Overview

Boston Scientific Corporation (BSX) trades on NYQ as part of the Healthcare peer group (Medical Devices).

BSX — Business Description

BSX represents a Medical Devices business in the Healthcare segment. Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in two segments, MedSurg and Cardiovascular. It offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, SpyGlass, single-use scopes used for diagnostic and therapeutic procedures in the pancreaticobiliary system, in endoscopic retrograde cholangiopancreatography procedures, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention products; devices to treat urological conditions, including uretera…

Official website: https://www.bostonscientific.com.

BSX — Investment Thesis

At a high level, BSX offers exposure to Healthcare with metrics outlined below from public market data.

• Revenue is expanding at roughly 7.5% year-over-year (public data).
• Trailing P/E of 18.21× sits in a moderate band relative to high-growth peers.
• Forward P/E (13.05×) is below trailing P/E — earnings may be expected to improve.
• Equity market capitalization is approximately $64.66B.

See the free estimates and earnings pages for public targets and growth metrics. Ownership, live news, and deeper models remain in Vest Terminal.

BSX — Financial Health

Key financial health indicators for Boston Scientific Corporation are derived exclusively from public data — no proprietary estimates.

Profit margin of 17.5% indicates solid bottom-line conversion. Positive free cash flow of $2.45B supports balance-sheet flexibility.

BSX — Growth Outlook

Growth outlook for Boston Scientific Corporation (BSX) depends on demand trends in Medical Devices and the company's ability to convert revenue into sustainable earnings.

• Revenue growth of 7.5% suggests steady but measured expansion.
• Earnings growth of 15.1% year-over-year supports improving profitability.
• Price is 57.8% below the 52-week high.
• Shares trade 5.7% above the 52-week low — limited rebound so far.

BSX — Competitive Position

Boston Scientific Corporation (BSX) is evaluated against peers on scale, margin structure, and capital efficiency within Healthcare.

• Competes within Healthcare, specifically in Medical Devices.
• Market capitalization of $64.66B places BSX among large-cap peers.
• Gross margin near 69.2% may reflect pricing power or favorable mix.

BSX — Summary

Boston Scientific Corporation (BSX) is a large-cap Healthcare company focused on Medical Devices, listed on NYQ. Last price $44.62 with market cap $64.66B. Trailing P/E 18.21×. Revenue grew 7.5% year-over-year per public data. Notable strengths include revenue growth of 7.5% year-over-year. Key watch items include price 58% below the 52-week high — sustained negative sentiment. Premium Terminal tools for Boston Scientific Corporation add ownership analytics, news, and richer estimate history beyond this public summary.